Twitter Facebook LinkedIn YouTube

BioSyent (TSXV: RX) subject of a StockPotentials report by Toronto-based eResearch Corporation

Video Platform Video Management Video Solutions Video Player

StockPotentials reports cover smaller companies that eResearch believes would be primarily of interest to retail investors. BioSyent, which trades on the TSX Venture Exchange under the symbol RX, is a Toronto-based, growth oriented, independent pharmaceutical company.

Additional Information:

Company: BioSyent
Website: http://www.biosyent.com/rx/home/
Stock Symbol: TSXV: RX.V
Date Published: Jul 7, 2014
Transcript: Available

Video Transcript:

I’m Renee Hammond for Investmentpitch Media

BioSyent was recently the subject of a StockPotentials report by Toronto-based eResearch Corporation.

StockPotentials reports cover smaller companies that eResearch believes would be primarily of interest to retail investors.

BioSyent, which trades on the TSX Venture Exchange under the symbol RX, is a Toronto-based, growth oriented, independent pharmaceutical company.

On the Pharma side, the company sources new products from partnerships in Europe and the U.S., in-licensing exclusive Canadian marketing rights to the products.

The company then manages each product through the regulatory and registration process with Canadian government authorities and, after approval, begins marketing the product in Canada.

BioSyent also has a small Insecticide business, which manufactures and markets a bio-friendly product used in the protection of stored grain.

This product, which accounts for 10.6% of 2013 revenue, is marketed in Canada and the U.S.

eResearch first profiled BioSyent in April 2012, when the company was trading at just $0.57 a share, with a capitalization of $7.1 million.

27 months later, BioSyent is now trading at $$7.30, and with approximately 13.8 million shares outstanding, is capitalized at $100.8 million.

Over the past four years, sales have grown from $1.7 million to $7.8 million, with earnings increasing from $48,000 to $1.9 million.

At March 31, 2014, the company had $3.8 million in cash, and working capital of $5.0 million.

BioSyent started 2014 with a product portfolio consisting of 3 products, and received Health Canada approval for 3 more products, and is waiting for approval of another urgent care product which was submitted to Health Canada in 2013.

If approved, this will bring the company’s total product portfolio to 7 products compared with only 3 at the beginning of this year.

For more information about BioSyent please visit their website at www.biosyent.com or contact René Goehrum, President & CEO at 905-206-0013 ext.320 or email rgoehrum@biosyent.com.

For a copy of eResearch’s report, or to access their extensive daily market commentary, please visit their website at www.eresearch.ca.

I’m Renee Hammond for Investmentpitch Media
For more video news, and to view our disclaimer, be sure to visit our website www.investmentpitch.com.
This video is for information purposes only and it is not a recommendation to buy or sell any securities.